By Cristina Roca

Bayer AG said late Thursday that it now expects peak sales for Nubeqa to top 3 billion euros ($3.41 billion) after disclosing positive Phase 3 trial data for the drug.

The German chemical and pharmaceutical company said Nubeqa, an oral androgen receptor inhibitor, in combination with androgen deprivation therapy and docetaxel, significantly increased overall survival in patients with metastatic hormone-sensitive prostate cancer.

Write to Cristina Roca at cristina.roca@wsj.com

(END) Dow Jones Newswires

February 18, 2022 03:12 ET (08:12 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Bayer.
Bayer (TG:BAYN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Bayer.